Hypoxia is a key feature of most solid tumours and underlies many of the processes associated with how cancer progresses; including tumour cell survival and proliferation, genetic instability, immune responses, angiogenesis, invasion and metastasis and metabolic adaptive responses. Hypoxia inducible factors (HIFs) are a highly evolutionarily conserved family of dimeric transcription factors that are central to mediating the cellular response to hypoxia by regulating the expression of a diverse array of targets. Hypoxia and HIF activation is associated with treatment failure, resistance and poor clinical outcomes. Thus its analysis in vitro and in vivo is a key part of tumour biology and translational research.
In this webinar we will discuss:
- Role of hypoxia in therapy resistance radio therapy and many other modalities-
- Hormones chemo and immunotherapy
- Role of HIF and HIF targets in tumour biology-potential for therapy
- In vitro experimental models 2D and 3D
- The importance of oxygen concentration in our lab models, and how to measure it.
The webinar will also discuss relevant in vitro experimental models, and introduce new approaches being developed by the EC-funded MetaCell-HS consortium, combining advanced plate reader technologies (CLARIOstar® with ACU, BMG Labtech) and intracellular fluorescent probes (MitoXpress® Intra Intracellular Oxygen Assay, Luxcel Biosciences) to enable researchers to monitor and control cellular oxygenation in vitro.
For Research Use Only. Not for use in diagnostic procedures.